Floatz logo

METRONIDAZOLE

Rectal Adenocarcinoma

AC Camargo Cancer CenterSmall moleculePhase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
73/ 100

Competitive context

41 Active assets in the Rectal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 3BBB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BBB
Eloxatin
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3BBB
Eloxatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Cetuximab
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB

View all 50 →

Same molecule, other indications

METRONIDAZOLE is also rated in:

Surgical Site InfectionDormant
BBB
Indicative ·
72 / 100
View asset →
colorectal neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
Surgery--ComplicationsDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →